Polaris Market Research today announced findings from its latest report, projecting the U.S. CRISPR & Cas genes market to grow from USD 1.54 billion in 2024 to USD 8.29 billion by 2034, at a CAGR of 18.4% between 2025 and 2034. The 129-page report profiles leading companies across product, service, application, and end-use segments shaping the country's gene-editing landscape.

CRISPR-Cas genes refer to a natural bacterial defense system adapted for gene editing, in which CRISPR sequences guide the Cas enzyme to specific DNA locations to make precise cuts, enabling targeted modification of genes for research and therapeutic purposes. In the U.S., government agencies and private investors are pouring capital into genomics and biotechnology, with National Institutes of Health funding supporting advanced gene-editing research alongside a wave of biotech IPOs and venture financing. Artificial intelligence is increasingly woven into this pipeline as well, helping researchers analyze large genomic datasets, optimize enzyme design, and better understand off-target effects to improve the safety of CRISPR-based therapies.

Analyst Commentary on U.S. CRISPR & Cas Genes Market Growth

"The U.S. continues to lead the world in translating CRISPR research into real clinical pipelines, thanks to strong NIH funding and a regulatory framework that rewards fast-tracked innovation," said a Senior Research Analyst at Polaris Market Research. "The market growth we're tracking in contract research organizations shows where the opportunity lies for buyers looking to outsource specialized gene-editing work."

U.S. CRISPR & Cas Genes Market Statistics at a Glance

• 2024 Market Size: USD 1.54 Billion
• 2025 Market Size: USD 1.81 Billion
• 2034 Projected Size: USD 8.29 Billion
• CAGR (2025–2034): 18.4%
• Largest Segment (2024): Kits & Enzymes (by Product)

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: The rising prevalence of genetic disorders and a favorable regulatory and ethical framework for gene editing are the primary forces behind the market's rapid expansion, alongside growing investment from the National Institutes of Health and private biotech funding. The Cystic Fibrosis Foundation reports that roughly 40,000 children and adults in the U.S. live with cystic fibrosis, one of many genetic conditions pushing researchers toward permanent CRISPR-based cures rather than lifelong treatments. Companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are advancing late-stage clinical trials for conditions including sickle cell anemia and beta-thalassemia, often in partnership with larger pharmaceutical companies. The FDA and NIH provide structured, adaptive regulatory pathways, including fast-track designations for rare-disease therapies, that let researchers and companies move from lab to clinic with greater confidence. In May 2025, Biomay AG launched its FDA-grade CRISPR/Cas9 nuclease for off-the-shelf purchase, expanding access to GMP-grade gene-editing reagents for U.S. researchers. High regulatory complexity and ongoing ethical concerns around gene editing remain a restraint in certain applications, even as continued advances in DNA sequencing and synthetic biology keep improving CRISPR's overall accuracy and efficiency.

Major Companies Covered: Thermo Fisher Scientific, Merck KGaA, CRISPR Therapeutics, Danaher Corporation, and Caribou Biosciences, Inc.

Segments Covered: By Product (Kits & Enzymes, Libraries, Design Tool, Antibodies, Other Products), By Service (Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis), By Application (Biomedical, Agricultural), By End Use (Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, Contract Research Organizations).

👉 Download a Free Sample of the U.S. CRISPR & Cas Genes Market Report → 

https://www.polarismarketresearch.com/industry-analysis/us-crispr-and-cas-genes-market 

Recent Developments in the U.S. CRISPR & Cas Genes Market

• May 2025: Biomay AG, an FDA-approved GMP manufacturer, launched its FDA-grade CRISPR/Cas9 nuclease for off-the-shelf purchase, supplying high-quality Cas9 nuclease for scalable, compliant gene-editing applications.

Segment Snapshot: Kits & Enzymes Lead, CROs Gain Ground

The kits and enzymes segment held the largest product share in 2024 and is projected to register a CAGR of 19.3% through 2034, driven by widespread use of ready-to-use gene-editing tools across academic and commercial research, alongside advances in enzyme engineering that improve specificity for precision-medicine and drug-discovery applications. The agricultural application segment accounted for 14.03% of total revenue in 2024, supported by favorable regulatory policies for CRISPR-edited crops. By end use, contract research organizations held a 15.59% revenue share in 2024, as pharmaceutical and biotechnology companies increasingly outsource specialized CRISPR-related research, including cell line development and preclinical validation, to reduce costs and accelerate timelines.

Why It Matters for Investors Evaluating the Gene-Editing Pipeline

For stakeholders researching the U.S. CRISPR & Cas genes market forecast, the underlying Polaris Market Research report benchmarks market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions with confidence.

More Trending Latest Reports By Polaris Market Research:

energy-drink-market

artificial-intelligence-ai-in-pharmaceutical-market

mosquito-repellent-market

dpu-smartnic-market

carbon-nanotubes-market

powder-metallurgy-market